Research progress of Chinese medicine combined with tumor-targeted drugs in the treatment of non-small cell lung cancer
WEN Li WANG Li
Department of Respiratory and Critical Care Medicine,the First Affiliated Hospital of Guangxi University of Chinese Medicine,Guangxi Zhuang Autonomous Region,Nanning 530023,China
Abstract：In recent years,the incidence and mortality of lung cancer have risen sharply,ranking first among cities.The treatment of lung cancer needs to adopt a multi-disciplinary comprehensive treatment model based on the patient's physical condition,cytology,tumor,pathological type,etc.,and focus on individualized treatment.Non-small cell lung cancer is the most common type of lung cancer,and it is also one of the diseases with high mortality of lung cancer,Targeted therapy is the preferred treatment option for non-small cell lung cancer.With the expansion of the use of targeted drugs,the emergence of drug resistance and adverse reactions slowed the treatment process.At present,Chinese medicine combined with tumor-targeted drugs in the treatment of non-small cell lung cancer has become a research hotspot.Relevant studies have shown that Chinese medicine combined with tumor-targeted drugs can improve survival rate and quality of life,reduce adverse reactions and delay the time for patients to develop drug resistance.This article will further summarize the research of Chinese medicine combined with tumor-targeted drug therapy in the field of non-small cell lung cancer,in order to provide a theoretical basis for Chinese medicine combined with tumor-targeted drug therapy,and provide a theoretical basis for prevention of drug resistance and clinical treatment.
文礼;王丽. 中医药联合肿瘤靶向药物治疗非小细胞肺癌的研究进展[J]. 中国当代医药, 2022, 29(10): 29-33.
WEN Li ;WANG Li. Research progress of Chinese medicine combined with tumor-targeted drugs in the treatment of non-small cell lung cancer. 中国当代医药, 2022, 29(10): 29-33.
Lin R，Chen R，Chen Z，et al.Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations：Case Report and Literature Review[J].Front Oncol，2021，11：731572.
[13]
Xu H，Zhang Q，Liang L，et al.Crizotinibvsplatinum -based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants[J].Cancer Med，2020，9（10）：3328-3336.
[14]
Liu C，Yu H，Chang J，et al.Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non Small-Cell Lung Cancer in Routine Clinical Practice[J].Target Oncol，2019，14（3）：315-323.
京公网安备 11010502046607号